Pluri (PLUR) EPS (Basic) : $-3.62 (TTM As of Mar. 2025)

View and export this data going back to 1991. Start your Free Trial

What is Pluri EPS (Basic)?

Pluri's basic earnings per share (Basic EPS) for the three months ended in Mar. 2025 was $-0.94. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Mar. 2025 was $-3.62.

Pluri's EPS (Diluted) for the three months ended in Mar. 2025 was $-0.94. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Mar. 2025 was $-3.62.

Pluri's EPS without NRI for the three months ended in Mar. 2025 was $-0.79. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Mar. 2025 was -3.64.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

Pluri EPS (Basic) Historical Data

The historical data trend for Pluri's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pluri EPS (Basic) Chart

Pluri Annual Data

Trend

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Jun24

EPS (Basic)

Get a 7-Day Free Trial

-12.80

-14.16

-10.24

-6.24

-3.99

Pluri Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
EPS (Basic)	Get a 7-Day Free Trial															-1.01	-1.07	-1.08	-0.53	-0.94

Pluri EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

Pluri's Basic EPS for the fiscal year that ended in Jun. 2024 is calculated as

Basic EPS (A: Jun. 2024 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(-20.888	-	0)	/	5.240
	=	-3.99

Pluri's Basic EPS for the quarter that ended in Mar. 2025 is calculated as

Basic EPS (Q: Mar. 2025 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(-6.147	-	0)	/	6.564
	=	-0.94

EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $-3.62

Pluri (NAS:PLUR) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Pluri EPS (Basic) Related Terms

Thank you for viewing the detailed overview of Pluri's EPS (Basic) provided by GuruFocus.com. Please click on the following links to see related term pages.

Pluri Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Pluri Inc (NAS:PLUR) » Definitions » EPS (Basic)

Comparable Companies

Traded in Other Exchanges

PLUR:Israel

Address

MATAM Advanced Technology Park, Building No.5, Haifa, ISR, 3508409

Website

https://www.pluri-biotech.com

Pluri Inc is a biotechnology company, that creates cell-based products for commercial use and is pioneering a biotech revolution that promotes wellbeing and sustainability. The company's technology platform developed a three-dimensional, or 3D, technology platform for cell expansion with an industrial scale in-house Good Manufacturing Practice, or GMP, cell manufacturing facility. It uses its technology in the field of regenerative medicine, food tech and agricultural technology or agtech.

Executives

Lorne Kenneth Abony	director	MATAM PARK, BUILDING #5, HAIFA L3 3508409
Zami Aberman	officer: Chief Executive Officer	63 RABUTZKY STREET, RAANANA L3 43220
Varda Shalev	director	MATAM PARK, BUILDING #5, HAIFA L3 3508409
Pinhas Doron Birger	director	MATAM PARK, BUILDING #5, HAIFA L3 3508409
Clover Wolf Capital - Limited Partnership	10 percent owner	BOODENHIMER 24, TEL AVIV L3 6200838
Rami Avraham Levi	director	MATAM ADVANCED TECHNOLOGY PARK, BUILDING NO. 5, HAIFA L3 3508409
Maital Shemesh-rasmussen	director	MATAM ADVANCED TECHNOLOGY PARK, BUILDING NO. 5, HAIFA L3 3508409
Doron Shorrer	director	33 KOREH PLADORR ST, JERUSALEM L3 93393
Isaac Braun	director	9 ZEHARIA STREET, BENE BARAK L3 51540
Yaky Yanay	officer: Chief Financial Officer	ARGAMAN 14, SHIMSHIT L3 17906
Moria Kwiat	director	HAKFAR 11, KIRYAT ONO L3 55525
Israel Ben-yoram	director	24 BARKAN STREET, RISHON LEZION L3 00000
Chen Franco-yehuda	officer: Chief Financial Officer	MATAM ADVANCED TECHNOLOGY PARK, BUILDING NO. 5, HAIFA L3 31905
Mark Germain	director	WELLSFORD REAL PROPERTIES INC, 535 MADISON AVENUE, NEW YORK NY 10022
Erez Egozi	officer: Chief Financial Officer	MATAM PARK, BUILDING 05, HAIFA L3 31905